Thus, there is a high prevalence of signs and symptoms of TMD in FM patients, indicating the need for an integrated diagnosis and treatment of these patients, which suggest that the FM could be a medium- or long-term risk factor for the development of TMD.

Treatment survival with biological therapy may be influenced by many factors, and it seems to be different among various rheumatic diseases and biological agents. The goal of the study was to compare the drug survival and the causes of discontinuation of anti-tumoral necrosis factor (anti-TNF) therapy in ankylosing spondylitis (AS) with rheumatoid arthritis (RA). Study participants were a cohort from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (BIOBADABRASIL) between 2008 and 2012. The observation time was up to 4 years following the introduction of the first treatment. Gender, age, disease duration, disease activity, comorbidities, and concomitant therapies were assessed. A total of 1303 patients were included: 372 had AS and 931 had RA in which 38.7 % (n = 504) used infliximab (IFX), 34.9 % (n = 455) used adalimumab (ADA), and 26.4 % (n = 344) used etanercept (ETA). The anti-TNF drug survival of patients with AS was 63.08 months (confidence interval (CI) 60.24, 65.92) and patients with RA was 47.5 months (CI 45.65, 49.36). It was significant higher in AS (log-rank; p ≤ 0.001). Patients with RA discontinued anti-TNF more than patients with AS when adjusted to gender and corticosteroid. The adjHR (95 % CI) was 1.6 (1.14, 2.31). Female patients who were also corticosteroid users, but not of advanced age, have shown lower survival for both diseases (log-rank, p ≤ 0.001). The discontinuation rate of IFX, but not of ADA or ETA, was significantly higher in RA than in SA; HR (95 % CI) was 2.49 (1.46, 4.24). The main causes of discontinuation were ineffectiveness and adverse event in both diseases. AS patients have better drug survival adjusted to gender, age, and corticosteroid. This results appear to be related to the disease mechanism.

The incidence of tuberculosis was higher among users of synthetic DMARDs and anti-TNF than among users of synthetic DMARDs and synthetic DMARDs and non-anti-TNF biologics and also occurred later, suggesting infection during treatment and no screening failure.

Este estudo teve como objetivo identificar a frequência de sintomas ansiosos e depressivos verificando a associação entre a ansiedade-traço, sintomas atuais de depressão e ansiedade nos fibromiálgicos. Foram entrevistados 60 sujeitos com diagnóstico de fibromialgia no Ambulatório de Reumatologia da Universidade Federal de Sergipe, entre agosto de 2007 a março de 2008, sendo aplicados dois questionários: Escala Hospitalar de Ansiedade e Depressão (EHAD) e o Inventário de Ansiedade Traço-Estado (IDATE-T). A frequência de sintomas depressivos e ansiosos foi, respectivamente, de 50% e 86% para os fibromiálgicos e a média do escore do traço ansioso foi de 59,38. Detectou-se associação entre a ansiedade-traço e estado. A ansiedade e a depressão foram sintomas frequentes nos pacientes com fibromialgia. Entretanto, a ansiedade revelou-se um sintoma secundário mais frequente que a depressão, apresentando-se uma forma mais grave, sendo uma comorbidade que deve ser melhor valorizada e estudada.

Background The safety profile of biologic drugs might present substantial regional differences. Since 2009, the Brazilian Society of Rheumatology has maintained BIOBADABRASIL (Brazilian Registry for Biologic Drugs), a registry for monitoring of biologic therapies in rheumatic diseases. Objectives The aim of this study was to verify the incidence rate (IR) of serious infections in rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients on biologic drugs. Methods BIOBADABRASIL prospectively included patients with rheumatic diseases who started the first biologic drug or a synthetic disease-modifying antirheumatic drug as a parallel control group. This study focuses on serious infectious adverse events (SIAEs) in RA and SpA patients on biologic drugs compared with controls, from January 2009 to June 2015. Time of exposure was set from initiation of the drug to the date of last administration or censorship. Serious infectious adverse events IR was calculated per 1000 patient/years with 95% confidence interval (CI). Results A total of 1698 patients (RA, 1121; SpA, 577) were included, 7119 patient/years. Serious infectious adverse events were more common among patients on tumor necrosis factor inhibitors (TNFi's) than controls (adjusted IR ratio, 2.96 [95% CI, 2.01–4.36]; p < 0.001). Subsequent TNFi was associated with a higher SIAEs incidence when compared with first TNFI (adjusted IR ratio, 1.55 [95% CI, 1.15–2.08]; p = 0.004). Serious infectious adverse events were associated with age and corticosteroids intake. Serious infectious adverse events were more frequent in the respiratory tract in all subgroups. Conclusions In BIOBADABRASIL, biologic drugs, especially the subsequent TNFi, were associated with a higher risk of serious infections compared with synthetic DMARDs. Corticosteroid intake and age represented risk factors for SIAEs. Constant monitoring is required to follow the safety profile of drugs in the clinical setting of rheumatic conditions in Brazil.

Three cases are reported of disseminated infection due to Fusarium species in severely neutropenic patients. The clinical findings in all patients included fever, painful disseminated nodular skin lesions and severe myalgia. The outcome was fatal despite early administration of amphotericin B. The portal of entry of the organism was probably the nasal sinus in two cases.

Systemic sclerosis is a rare autoimmune rheumatic connective tissue disease, progressive of unknown etiology and variable evolution. Reaches vital organs and perioral tissues, causing limitation of mouth opening, stiffness of the articulators, face mask with appearance, difficulty in chewing and swallowing. Aiming to compare the pre and post intervention miofuncional speech orofacial in subjects with systemic sclerosis was performed qualiquantitativo exploratory clinical study in Rheumatology department of the University Hospital and Clinic, School of Speech Pathology, Federal University of Sergipe, from July / 2012 to December / 2013. The sample consisted of five individuals, of both genders, aged between 24 and 60 years and confirmed medical diagnosis of that condition. The subjects underwent evaluation by MBGR protocol and speech therapy (myofunctional and myoterapica), totaling 36 sessions. At the end, the initial and final results were compared from clinical indicators worked. After analyzing the results, improvements in all aspects worked were observed. The previous assessment of speech therapy revealed restriction of mouth opening in all subjects and the final results showed gains between 5.3 and 14.2mm opening (average: 9.26). Regarding tone, mobility of the articulators and orofacial numbness observed improvements and evidence of adequacy of oral functions. Can be concluded that although some patients still show changes in speech rehabilitation promoted significant improvements in clinical and quality of life of these individuals. Keywords: Speech, Language and Hearing Sciences; Scleroderma, Systemic; Speech Therapy RESUMO A Esclerose Sistêmica é uma doença reumática autoimune do tecido conjuntivo, progressiva, pouco frequente, de etiologia desconhecida e com evolução variável. Atinge órgãos nobres e tecidos periorais, causando limitação na abertura da boca, hipertonia dos órgãos fonoarticulatórios, face com "aparência de máscara", dificuldades na mastigação e deglutição. Com o objetivo de comparar os resultados pré e pós-intervenção fonoaudiológica miofuncional orofacial em sujeitos com esclerose sistêmica, realizou--se estudo clínico exploratório qualiquantitativo no setor de Reumatologia do Hospital Universitário e na Clínica escola de Fonoaudiologia da Universidade Federal de Sergipe, no período de julho/2012 a dezembro/2013. A amostra foi composta por cinco indivíduos, de ambos os gêneros, com faixa etária entre 24 e 60 anos e diagnóstico médico confirmado da referida afecção. Os indivíduos passaram por avaliação por meio do protocolo MBGR e 36 sessões de terapia fonoaudiológica (miofuncional e mioterápica). Ao término, os resultados iniciais e finais foram comparados a partir dos indicadores clínicos trabalhados. Diante da análise dos resultados obtidos, foram observadas melhoras em todos os aspectos trabalhados. A avaliação anterior à fonoterapia revelou restrição na abertura da boca em todos os indivíduos e os resultados finais apresentaram ganhos entre 5.3 e 14.2 mm de abertura (média: ...

In the Results section, under the subheading, "Comparison of MTX + LEF with MTX/LEF, " the first sentence in the third paragraph should not include adjusted HRs (aHRs) as the values refer to crude incidence: "Considering the risk of laboratory abnormalities comparing MTX + LEF with the MTX or LEF group, there were numerically higher incidence of anemia (0.7, 95% CI 0.4-1.2 per 100 PY vs 0.4, 95% CI 0.2-0.6 per 100 PY, respectively), and elevation of hepatic transaminases (0.6, 95% CI 0.3-1.1 per 100 PY vs 0.3, 95% CI 0.1-0.5 per 100 PY, respectively) in the former group." In the Table 3 footnotes, biologic DMARDs/tofacitinib should not be included in the legend "b". The correct legend is, " b Adjusted for age, baseline DAS28, disease duration, sex, current smoking, seropositivity for rheumatoid factor or anti-CCP, history of malignancy, diabetes, hypertension, hypercholesterolemia, renal failure, ischemic cardiomyopathy, COPD, heart failure, use of sulfasalazine, antimalarials, corticosteroids, starting year, osteoporosis, and hepatitis B and C." The errors do not affect the results or conclusions of the study.